Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPO for Persistent Symptoms After TBI
NCT02226848Phase 2Withdrawn
- Sponsor
- National Institute of Neurological Disorders and Stroke
- Start
- Aug 2014
- Primary completion
- May 2017
- Modality
- Recombinant Proteins and Enzymes
01
Overview
A Phase 2 trial of erythropoietin in traumatic brain injury (TBI), sponsored by National Institute of Neurological Disorders and Stroke. Planned start Aug 2014; status: withdrawn.
02
Drugs
erythropoietin
03
Conditions
traumatic brain injury (TBI)
Beyond the preview
Go deeper on NCT02226848.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02226848.